Bayer Scores Supreme Court Knockout, but the Fight Over Its Future Is Far From Over
Veröffentlicht: 25.06.2026 um 21:24 Uhr, Redaktion boerse-global.de
The US Supreme Court has handed Bayer a landmark legal victory, striking down a jury verdict that had exposed the German conglomerate to tens of thousands of Roundup-related lawsuits. Shares of the Dax-listed company surged 14.92 percent to €45.83 on the day – the strongest intraday jump in Frankfurt since March 2003. The ruling, delivered by a 7-to-2 majority, holds that consumers cannot sue Bayer for failing to include a cancer warning on Roundup labels because the Environmental Protection Agency had already deemed such a warning unnecessary.
Yet the decision, while transformative, does not wipe the slate entirely clean. Bayer is still trying to secure final approval for a $7.25 billion class-action settlement covering around 65,000 open claims. That hearing is scheduled for early July. The Supreme Court ruling, coming just ahead of that date, dramatically strengthens Bayer's hand at the negotiating table. If the settlement is approved, the company’s legal overhang would be largely contained. If it stalls, however, plaintiffs' lawyers may try to pivot to alternative liability theories – a risk highlighted by Justice Ketanji Brown Jackson in her dissenting opinion.
The financial toll of the Roundup saga has been enormous. Bayer has already spent more than $10 billion on litigation and payouts. For 2026 alone, the company had budgeted around €5 billion for legal disbursements. That burden now looks set to shrink significantly, accelerating the deleveraging effort already under way. Net debt fell from €32.6 billion at the end of 2024 to €29.8 billion by the close of 2025, supported by free cash flow of €2.1 billion last year. The trouble is that management expects negative free cash flow in 2026, partly because existing settlement payments still need to be funded through debt and bonds.
While the legal drama dominates headlines, Bayer is quietly building a pharmaceutical pipeline to replace fading blockbusters. In June, the group closed the acquisition of Perfuse Therapeutics for an upfront $300 million, with milestone payments that could lift the total value to $2.45 billion. The target is PER-001, a Phase II intravitreal implant for glaucoma and diabetic retinopathy. More strategically critical is asundexian, an oral Factor XIa inhibitor for stroke prevention. Bayer has filed for approval with the EMA, FDA, and China’s drug regulator, all of which have granted priority review. Japan is also in the pipeline. This is the first-ever submission of a Factor XIa inhibitor in Europe, and the drug is intended to plug the hole left by Xarelto, whose revenue tumbled by a third to €2.6 billion in 2025 as patents expired. Similar erosion is expected in 2026.
Should investors sell immediately? Or is it worth buying Bayer?
On the research front, Bayer struck a cooperation deal with Iambic Therapeutics at the end of June, using artificial intelligence to discover new drug candidates. The typical development timeline – up to 15 years and costing $2.6 billion – could be drastically shortened by the AI platform. The move signals that management is thinking long-term even as short-term cash pressures mount.
The stock’s rally has already repriced it substantially. Shares are now trading about 25 percent above the 200-day moving average of €36.48. Since the start of the year, the gain stands at 20.53 percent. The 52-week high of €49.93 is now within striking distance if the July settlement hearing goes Bayer’s way, while the former low of €25.09 seems a distant memory. But technical indicators flash caution: the relative strength index sits near 80, suggesting a market that is overbought, while annualized volatility of 53.70 percent warns that sharp pullbacks are possible.
For CEO Bill Anderson, whose contract was extended until March 2029, the Supreme Court ruling removes the biggest drag on the company’s story. But not all shareholders are celebrating. Some continue to push for a breakup, including a possible sale of the over-the-counter drugs division. The legal progress does not erase the €29.8 billion in net debt, nor does it guarantee that the July settlement will be approved without a spike in opt-out rates.
Bayer at a turning point? This analysis reveals what investors need to know now.
If the settlement clears, the focus will shift squarely to operational delivery. Bayer has pledged €2 billion in cost savings by the end of 2026 – a target that will test whether the legal and financial tailwinds can translate into sustainable earnings growth. For now, the stock’s trajectory depends on whether the Supreme Court knockout proves to be the start of a sustained recovery or just a one-two punch against a still-wobbly opponent.
Ad
Bayer Stock: New Analysis - 25 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer zu unseren Artikeln: Keine Anlageberatung, keine Kauf oder Verkaufsempfehlung. Angaben zu Kursen, Unternehmen und Märkten ohne Gewähr; Änderungen jederzeit möglich. Börsengeschäfte können zu hohen Verlusten führen. Unsere Beiträge werden ganz oder teilweise automatisiert mit Unterstützung von AI erstellt und geprüft.
